Novartis boosts US respiratory portfolio with two COPD filings
This article was originally published in Scrip
Novartis has filed new drug applications (NDAs) for two chronic obstructive pulmonary disease (COPD) drugs: QVA149 (indacaterol/glycopyrronium bromide) and NVA237 (glycopyrronium bromide).
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.